UBS downgraded Nanobiotix (NBTX) to Neutral from Buy with a price target of $3.50, down from $12, as a new analyst assumed coverage of the stock. The next major catalyst is more than 12 months away and the firm sees a near-term financing overhang limiting potential upside, the analyst tells investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX: